Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations.

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 315-334

  Basile, Kevin J ^a   Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug tolerance; Stem cell; Subpopulations

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; ETOPOSIDE; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE H3; JUMONJI AT RICH INTERACTIVE DOMAIN CONTAINING PROTEIN 1A; JUMONJI AT RICH INTERACTIVE DOMAIN CONTAINING PROTEIN 1B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; RAF PROTEIN; SOMATOMEDIN C; SORAFENIB; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXD3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; VORINOSTAT;

ADAPTATION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DRUG EFFICACY; DRUG TOLERANCE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE; ONCOGENE N RAS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADIOSENSITIVITY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84865852492     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00010-5     Document Type: Chapter

References (55)

1. Abel E.V., Aplin A.E. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Research 2010, 70:2891-2900.
2. Atlasi Y., Mowla S.J., Ziaee S.A., Bahrami A.R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. International Journal of Cancer 2007, 120:1598-1602.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Basile K.J., Abel E.V., Aplin A.E. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 2012, 31:2471-2479.
5. Bhattacharyya N.P., Skandalis A., Ganesh A., Groden J., Meuth M. Mutator phenotype in human colorectal carcinoma cell lines. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:6319-6323.
6. Brown R., Hirst G.L., Gallagher W.M., McIlwrath A.J., Margison G.P., van der Zee A.G., et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15:45-52.
7. Burger H., van Tol H., Boersma A.W., Brok M., Wiemer E.A., Stoter G., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104:2940-2942.
8. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7950-7955.
9. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine 2011, 364:2507-2516.
10. Chen M.S., Woodward W.A., Behbod F., Peddibhotla S., Alfaro M.P., Buchholz T.A., et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. Journal of Cell Science 2007, 120(Pt 3):468-4477.
11. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., How C.K., Wang C.Y., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008, 3.
12. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Research 2010, 70:10433-10444.
13. Corcoran R.B., Diase-Santagata D., Bergethon K., Iafrate A.J., Settleman J., Engelman J.A. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling 2010, 3:1-10. ra84.
14. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
15. Davis R.L., Konopka J.B., Witte O.N. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Molecular and Cellular Biology 1985, 5:204-213.
16. Dhar N., McKinney J.D. Microbial phenotypic heterogeneity and antibiotic tolerance. Current Opinion in Microbiology 2007, 10:30-38.
17. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Molecular Cancer Research 2007, 5:981-989.
18. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
19. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology 2008, 26:2839-2845.
20. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. The Journal of Clinical Investigation 2010, 120:41-50.
21. Green H., Soderkvist P., Rosenberg P., Horvath G., Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clinical Cancer Research 2006, 12:854-859.
22. Grovdal L.M., Kim J., Holst M.R., Knudsen S.L., Grandal M.V., Deurs B.V. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 2012, 24:296-301.
23. Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell & Melanoma Research 2010, 23:190-200.
24. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
25. Hanna L.A., Foreman R.K., Tarasenko I.A., Kessler D.S., Labosky P.A. Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo. Genes & Development 2002, 16:2650-2661.
26. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
27. Kaplan F.M., Shao Y., Mayberry M.M., Aplin A.E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 2011, 30:366-371.
28. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology & Cell Biology 2011.
29. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 2006, 5.
30. Liu Y., Labosky P.A. Regulation of embryonic stem cell self-renewal and pluripotency by Foxd3. Stem Cells 2008, 26:2475-2484.
31. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007, 18:363-370.
32. Montagut C., Sharma S.V., Shioda T., McDermott U., Ulman M., Ulkus L.E., et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research 2008, 68:4853-4861.
33. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes & Development 1999, 13:2490-2501.
34. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 7326:973-977.
35. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine 2003, 348:994-1004.
36. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research 2011, 17:5530-5537.
37. Pan G., Li J., Zhou Y., Zheng H., Pei D. A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB Journal 2006, 20:1730-1732.
38. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3697-3702.
39. Pelaez I.M., Kalogeropoulou M., Ferraro A., Voulgari A., Pankotai T., Boros I., et al. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells. The International Journal of Biochemistry & Cell Biology 2010, 42:911-920.
40. Phillips T.M., McBride W.H., Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute 2006, 98:1777-1785.
41. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
42. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 2010, 464:427-430.
43. Rai K., Sarkar S., Broadbent T.J., Voas M., Grossmann K.F., Nadauld L.D., et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell 2010, 142:930-942.
44. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
45. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
46. Scheck A.C., Shaprio J.R., Coons S.W., Norman S.A., Johnson P.C. Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. Clinical Cancer Research 1996, 2:187-199.
47. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
48. Shao Y., Aplin A.E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research 2010, 70:6670-6681.
49. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
50. Strathdee G., MacKean M.J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999, 18:2335-2341.
51. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
52. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology 2011, 29:3085-3096.
53. Weisberg E., Griffin J.D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000, 95:3498-3505.
54. Whittaker S., Kirk R., Hayward R., Zambon A., Viros A., Cantarino N., et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Science Translational Medicine 2010, 2:1-10. 35ra41.
55. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:618-623.